STOCKHOLM, Dec. 30,
2022 /PRNewswire/ -- During December, Calliditas
Therapeutics AB (publ) has issued 415,000 common shares connected
to the company's long term incentive program 2019/2022. Thus, as of
December 30, 2022, the number of
shares and votes in the company amounts to 59,572,587 shares and
59,572,587 votes.
For further information, please contact:
Mikael Widell, Investor
relations
Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com
The information in the press release is such that Calliditas
Therapeutics AB (publ) is required to disclose pursuant to the
Swedish Financial Instruments Trading Act. The information was
submitted for publication, through the agency of the contact
persons set out above, at 08:00 CET
on December 30, 2022.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product, developed under the name Nefecon, has been granted
accelerated approval by the FDA under the trade name TARPEYO® and
conditional marketing authorization by the European Commission
under the trade name Kinpeygo®. Additionally, Calliditas is
conducting a Phase 2b/3 clinical
trial in primary biliary cholangitis and a Phase 2 proof-of-concept
trial in head and neck cancer with its NOX inhibitor product
candidate, setanaxib. Calliditas' common shares are listed on
Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares
are listed on the Nasdaq Global Select Market (ticker: CALT).
The following files are available for download:
|
https://mb.cision.com/Main/16574/3691084/1759706.pdf
|
Number of shares and
votes December 2022 (Eng)
|
View original
content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301711322.html
SOURCE Calliditas Therapeutics